Marina Biotech Announces a New Publication on Prestalia®

City of Industry, CA – February 27, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today further progress with its FDA-Approved Prestalia® hypertension drug, with the issuance of a new and independent publication on Prestalia®:  Elliott WJ Read More

Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio

City of Industry, CA – January 16, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that the Company has entered into a binding agreement with Autotelic Bio Inc., to enter into a license of Marina’s IT-103 Read More

Scroll Up